Skip to main content

Fiscal Wizard · Single-issue tearsheet

VIVS / Jun 21, 2026 Run #7280

VIVS

VivoSim Labs, Inc.

VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Composite verdict

F 16.2 / 100
Bearish setup · Directional State 12 drivers · 5 gates blocking
  • 52-Week Proximity
  • Rate of Change
  • Accumulation/Distribution Line
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 331st of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 18 signals100% Bear
Momentum Bearish 2Mean-reversion Neutral 48

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

32.4 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Revenue Growth (YoY) 100
Free Cash Flow Yield 0
Return on Capital Employed 76
FCF Margin 0
Greenblatt ROC 76
EPS Growth (YoY) 0

Technicals Bearish

0.0 / 100

Bearish setup leads (52-Week Proximity, Rate of Change, Accumulation/Distribution Line); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
52-Week Proximity 10
Rate of Change 11
Relative Strength vs SPY 15

Risk Gates

5 blocking 5 caution

5 guards active, 22 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for VIVS.